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A B S T R A C T
Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer diagnoses
worldwide. Most data on male breast cancer comes from small single-institution studies, and
because of the paucity of data, the optimal treatment for male breast cancer is not known. This
article summarizes a multidisciplinary international meeting on male breast cancer, sponsored by
the National Institutes of Health Office of Rare Diseases and the National Cancer Institute
Divisions of Cancer Epidemiology and Genetics and Cancer Treatment and Diagnosis. The meeting
included representatives from the fields of epidemiology, genetics, pathology and molecular
biology, health services research, and clinical oncology and the advocacy community, with a
comprehensive review of the data. Presentations focused on highlighting differences and
similarities between breast cancer in males and females. To enhance our understanding of male
breast cancer, international consortia are necessary. Therefore, the Breast International Group and
North American Breast Cancer Group have joined efforts to develop an International Male Breast
Cancer Program and to pool epidemiologic data, clinical information, and tumor specimens. This
international collaboration will also facilitate the future planning of clinical trials that can address
essential questions in the treatment of male breast cancer.
J Clin Oncol 28:2114-2122. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Male breast cancer is a rare disease, accounting for
less than 1% of all breast cancer diagnoses world-
wide. It is estimated that 1,910 men will be diag-
nosedwithbreast cancer in2009 in theUnitedStates
alone.1 Almost all data on male breast cancer come
from small single-institution studies, and because of
the paucity of data, the optimal treatment for male
breast cancer is not known. This article summarizes
a multidisciplinary meeting on male breast cancer,
sponsored by the National Institutes of Health
(NIH)OfficeofRareDiseasesandtheNationalCan-
cer Institute Divisions of Cancer Epidemiology and
Genetics and Cancer Treatment and Diagnosis and
held in Bethesda, Maryland on September 4, 2008.
The meeting included representatives from North
AmericaandseveralEuropeancountries in thefields
of epidemiology, genetics, pathology andmolecular
biology, health services research, and clinical oncol-
ogy and from the advocacy community. The main
goals of this multidisciplinary project were to build
on the joint efforts of theBreast InternationalGroup
(BIG) and North American Breast Cancer Group
(NABCG), to form a community of international
experts inmale breast cancer research to forge fruit-
ful andmeaningful collaborations, and to develop a
research program agenda by identifying the most
important research question(s) that we need an-
swered to enable the science to move forward.
The meeting presentations focused on high-
lighting differences and similarities between breast
cancer in males and females. International data on
malebreast cancer epidemiology, biology, and treat-
ment were reviewed, and the history of clinical trial
efforts for male breast cancer was presented. A par-
ticular focus was to consider when it is appropriate
to extrapolate data from female disease to the treat-
ment of male breast cancer and, conversely, when
specific trials areneeded toestablishoptimal therapy
for male breast cancer. The need for retrospective
and prospective data on treatment and outcomes,
biomarker studies, and the development of a tissue
repository was stressed.
EPIDEMIOLOGY
Male breast cancer accounts for less than 1% of all
cancers in men and less than 1% of breast cancers.
The Surveillance, Epidemiology, and End Results
(SEER) registry contains a total of 5,494 cases of
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male breast cancer and 835,000 cases of female breast cancer diag-
nosed from 1973 through 2005 (AndersonWF, submitted for publi-
cation). Eleven percent of breast cancers in men were in situ disease.
The median age at diagnosis among registry patients was slightly
older in men than women (67 v 61 years). Male breast cancer
incidence rates were slightly higher among black than white men.
Advanced stage-related tumor characteristics (tumor size  2.0 cm
and positive axillary lymph nodes) were more common in men than
women;mean tumor sizewas 2.4 cm (SE 0.03 cm) amongmen and
2.2 cm (SE  0.003 cm) among women. In contrast, advanced
biology-related variables (hormone receptor–negative expression
and high tumor grade) were more common among women than
men. For example, 23% and 7.6% of breast cancers were estrogen
receptor (ER)–negative among women and men, respectively. The
age-standardized incidence of male breast cancer increased slightly
from 1975 to 2000 (approximately 1% to 4%per year) and seemed to
plateau or decrease slightly from 2000 to 2005.
Age-specific incidence rate curves capture information about
both time trends in incidence and age at diagnosis. In the United
States, from 1973 to 2005, age-specific incidence rates for male breast
cancer increase linearly and steadily with age (Fig 1). In contrast, the
age-specific rates for female breast cancer increase rapidly until age 50
years and then continue to increase at a slower rate for older women.2
This phenomenon (in women), often referred to as Clemmesen’s
hook, has been attributed to a bimodal distribution with one peak of
early-onset disease and a second peak with a later age at onset. The
bimodal distribution is not seen formale breast cancer; rather, a single
peak ispresent at approximately 75yearsof age.Although theabsolute
rates of male breast cancer vary internationally, age-specific patterns
are similar worldwide.
In the Association of Nordic Cancer Registries database
(NORDCAN), age-standardized male breast cancer incidence from
1970 to2000 seemsquite stable at approximately 0.4%,withperhaps a
slight increaseduring the latterpart from1990onward, although these
trends should be interpreted with caution because of small numbers.
As expected,male breast cancer wasmore common in oldermen and
very uncommon in younger men. For all the Nordic countries to-
gether, there seems to be a relatively stable age-standardized incidence
of male breast cancer.3
RISK FACTORS AND GENETICS
Approximately 15% to 20%ofmenwith breast cancer report a family
history of breast or ovarian cancer. It is estimated that approximately
10% of men with breast cancer have a genetic predisposition, and
BRCA2 is themost clearly associated genemutation.4-7BRCA1muta-
tion is also associated,8 and associations have also been suggested for
PTEN, P53, and CHEK2.9-11 Klinefelter’s syndrome (XXY) has been
described in the literature as occurring in 3% to 7.5% of men with
breast cancer.12,13
Among male BRCA2 mutation carriers, the estimated lifetime
riskof breast cancer is 5%to10%comparedwith a general population
riskof0.1%.14Theassociationbetweenmalebreast cancerandBRCA1
mutations is not as strong as forBRCA2mutations.8,15,16 The lifetime
riskofmalebreast cancerwithBRCA1mutations is approximately 1%
to 5%.8,16,17 In 2002, Frank et al18 reported on the Myriad Genetics
database, which contained more than 10,000 individuals who had
undergone clinical testing for BRCA1/2 over a 3-year period. At that
time, there were only 76male breast cancers in their database, and 21
had detectable mutations; approximately one third of the mutations
were BRCA1mutations.
CHEK2 1100delC increases the risk of both male and female
breast cancer,particularly among individualswitha familyhistoryand
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Fig 1. Comparison of age at diagnosis for male and female breast cancer: Surveillance, Epidemiology, and End Results registry, 1973 to 2005. (A) Age-specific
incidence rates. (B) Age distribution at diagnosis.
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aCHEK2mutation.19,20 Itwas initially postulated thatCHEK2maybe
responsible for1%of femalebreast cancer andup to9%ofmalebreast
cancer, although these initial estimates were not based on data from
unselectedpopulations.CHEK2mutations are seenat a low frequency
in certain populations, including the US population. The example of
CHEK2 can also be applied to recent findings in genome-wide associ-
ation studies, which have already identified a number of single nucle-
otide polymorphisms associated with female breast cancer. Although
the relative risks associatedwith these low-penetrance genes are small,
they likely cause a substantial fraction of both hereditary and sporadic
breast cancer in men and women. Further information is needed
regarding interactions with other genes and environmental factors.
There are likely to be single nucleotide polymorphisms associated
specifically with male breast cancer, but because of small numbers,
there is limited power to look at this association, and the clinical value
of this information at this time is questionable.
Other well-described risk factors for breast cancer in men
include age, race, and radiation exposure. White men have an
incidence of 1.1 per 100,000, and blackmen have an incidence of 1.8
per 100,000.21 At all ages, black men have a higher incidence than
white men; in contrast, black women have a lower incidence of
breast cancer thanwhitewomen, except for at young ages (age 40
years). Blackmen also tend to have poorer prognostic features, such
as advanced-stage disease, larger tumor sizes, more nodal involve-
ment, and higher tumor grade, compared with their white counter-
parts.A cohort of atomicbombsurvivors showedamale breast cancer
rate of 1.8 per 100,000 person-years.22
Support for associations with other risk factors, derived mainly
from case-control studies, is less conclusive. These other risk factors
include hormonal factors, previous breast cancer, and environmental
exposures.23 A recent meta analysis23 showed an odds ratio of 2.7 for
the association between previous breast disease and male breast can-
cer. Gynecomastia has been described as a risk factor, although it is
unclearwhether gynecomastia is a risk factor formale breast cancer or
whether the risk factors formalebreast cancer are the sameas those for
gynecomastia. Exposure to electromagnetic fields has been postulated
to contribute to the risk of male breast cancer, although the data
are inconclusive.23,24
Data from case-control and cohort studies also suggest that in-
creased estradiol levels are associatedwithmale breast cancer. Cirrho-
sis of the liver, obesity, and exogenous estrogen result in increased
circulating estrogen levels and, therefore, may contribute to an in-
creased risk of male breast cancer.23,25,26 There are also possible asso-
ciationswith testicular abnormalities, which are thought to be a result
of low testosterone levels and alteration of the ratio of androgens
to estrogens.
Recently published data from the NIH American Association of
Retired Persons Diet and Health Study Cohort27 confirm an associa-
tion between family history and male breast cancer. These data also
suggest that obesity and osteoporotic fracture are risk factors. The
study included 324,000 male study participants, in whom the inci-
dence of subsequent male breast cancer could be assessed. Between
1995 and 2003, 121male breast cancers were identified, nine of which
were in situ and 107 of which were invasive (five patients hadmissing
stage information). The results confirmed that a family history of
breast cancer is an important risk factor. The correlationwas stronger
for patients who reported a sister alone compared with a mother
alone; the small numberof patientswho reportedboth amother anda
sister with breast cancer had a 10-fold increased risk for male breast
cancer. In this study,obesitywasalsoa significant risk factor.Menwith
a bodymass index of 30 had an 80% increased risk compared with
men with a body mass index of less than 25. Conversely, men who
werephysically active, especially in adolescence,were at a reduced risk,
although this was not statistically significant. The study also looked at
the relationship of alcohol consumption and cigarette smoking and
foundaslight increasedriskofmalebreast cancerassociatedwith these
factors,but therewasnodose-response relationship,probablybecause
of small numbers. An additional interesting finding was that a bone
fracture after the age of 45 years was a significant risk factor for male
breast cancer, with a relative risk of 2.20.
Men with breast cancer should be considered for genetic coun-
seling and testing, and an adequate family history should be obtained.
Current National Comprehensive Cancer Network guidelines for
men with BRCA1/2mutations recommend that providers teach and
encourage breast self-examination and perform twice-yearly clinical
breast examinations. In addition, consideration should be given to
baseline mammogram and annual mammography in men with gy-
necomastia or glandular breast density on the baseline study.Men are
advised to follow population screening guidelines for prostate cancer,
and there is an ongoing trial looking at prospective prostate cancer
screening for BRCA1 and BRCA2mutation carriers.28
Future studieswith larger cohorts areneeded tomore completely
describe the risk factors formale breast cancer. There is also a need for
studies that address howbiomarkersmay relate tomale breast cancer,
particularly with regard to endogenous hormones, and how these
relate to some of the identified risk factors such as obesity, physical
activity, and bone fractures. Ongoing work in genome-wide associa-
tion studies will likely provide further information regarding the ge-
netic basis of male breast cancer.
PROGNOSIS AND SURVIVAL
Overall, mortality from male breast cancer improved over the time
period from 1975 to 2005. Studies examining survival for male breast
cancer are quite small compared with population-based studies in
female breast cancer. Most studies report overall survival, although a
few more recent studies also look at disease-free survival. Five-year
survival rates formale breast cancer range from36% to 66%.29-38 The
broad range of survival is likely related to a mix of different stages of
disease and time frames of diagnosis, reflecting different treatment
guidelines (dates range from the 1930s to the 2000s). In general, men
are frequently diagnosed with more advanced-stage cancer than
women, particularly in regions where women are routinely screened
withmammography.
The largest published registry series to examine survival comes
from the National Cancer Database,39 which included 4,755 men
diagnosed with breast cancer between 1985 and 1994. Observed sur-
vival was highest for in situ disease (overall survival 82%; disease-
free survival  97%) and decreased with successive stages. In that
study, 36.9%, 41.9%, 9.6%, and 4.5% of men were diagnosed with
stage I, II, III, and IVdisease, respectively. In situdisease accounted for
7.1% of breast cancer diagnoses amongmen. Relative survival, which
takes into account age and life expectancy, was higher than observed
survival. This likely reflects the influence of greater intercurrent illness
as a result of an oldermean age at diagnosis. Data from several studies
Korde et al
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show that approximately 40%ofmenwith breast cancerwill die from
something other than their cancer. In the SEER database,40 raw data
suggest that men have poorer survival than women for stage I to III
disease.However, the relative survival rates, which adjust for older age
at diagnosis and poorer life expectancy inmen thanwomen, are quite
similar for men and women (Fig 2).
TheNORDCANdatabase showed an overall downward trend in
age-standardized mortality over time for both women and men.
Looking at total mortality broken down by (Nordic) country, the
highestmalebreast cancermortality ratewas inDenmark, followedby
Norway, Sweden, andFinland.Comparingbreast cancer–specific sur-
vival inmenandwomen inSweden, it seemedthat although in thefirst
5 years they were equivalent, after 5 years, women did statistically
significantly better than men; however, these data should be inter-
preted with caution because of small numbers (777 men compared
with approximately 130,000 women). For all the Nordic countries
together, there was perhaps a slight downward trend in mortality
for men.3
Race seems to be a prognostic factor in male breast cancer, par-
ticularly in the case of distant disease.41 Other prognostic factors are
similar towhat is seen inwomenwithbreast cancer.A2004analysis by
Giordano et al,40which included informationonapproximately 2,500
patients from the SEERdatabase, identified age, tumor size, stage, and
lymph node status as important in determining prognosis. This anal-
ysis did not show a correlation between hormone receptor status and
prognosis, butonly5-yearestimateswere stratifiedbyhormonerecep-
tor status because of lack of information in the older SEER data. Data
on human epidermal growth factor receptor 2 (HER2) inmale breast
cancer is sparse; therefore, it is difficult to draw any conclusions about
the effect of HER2 status on prognosis.
Men with a diagnosis of breast cancer are at increased risk of a
second primarymalignancy. In a SEER database review that included
4,873menwithbreast cancerdiagnosedbetween1973 and2003, there
was a 1.9% incidence of second primary male breast cancer.42 In this
study, 21% of men with breast cancer developed a second nonbreast
malignancy; the most commonly reported secondmalignancies were
prostate, colon, and genitourinary cancers.
HISTOPATHOLOGY AND MOLECULAR BIOLOGY
The diagnosis of male breast cancer is generally made on cytology or
corebiopsy.One studydescribing19years of experiencewith cytology
in male breast cancer43 found that more than two thirds of patients
had satisfactory specimens. Male breast tumors tend to be in the
areolar region. They are usually identified by palpation and generally
have associated mammographic and/or sonographic findings. Mam-
mographically, microcalcifications are less commonly seen in lesions
in men than in women.
In a recent reviewofmale breast cancer,44 themajority of tumors
were invasive ductal carcinoma (85% to 95%), followed by ductal
carcinoma in situ (5% to 10%). Invasive papillary carcinoma is more
common inmales than in females, accounting for approximately 2%
to 4% of breast cancers in men compared with up to 1% in women.
Informationon themolecularbiologyofmalebreast cancermust
be inferred from multiple, small, usually single-center studies using
immunohistochemistry because currently there are no actual data on
molecular subtypes in male breast cancer. The available literature
covers almost 60 studies with varying numbers of patients (up to
approximately 200 patients in the largest series) over more than two
decades. However, the majority of these studies are small (average of
34 to 39 patients per study) institutional series. Clearly, the combina-
tion of data from such diverse series, with different methodologies
and cut points for positivity for markers such as ER, progesterone
receptor (PgR), and HER2, means that such data must be inter-
preted with extreme caution. However, the existing data cover just
over 1,500 patients and may indicate some future research priori-
ties. Overall, data on conventional markers do not seem markedly
dissimilar to the data seen in female breast cancers. Table 1 sum-
marizes the existing literature on receptor status of male breast
cancer31,45-48 and compares the data with those seen in a large
representative data set of women from a large contemporary phase
III trial.49 Proportionately, male breast cancer seems to be more
hormone receptor positive (ER and PgR) than female breast can-
cers, in line with the SEER data cited earlier. Paradoxically, HER2
positivity also seems higher in male breast cancer than in female
breast cancer, but this contrasts with data collected from the SEER
database. These data may suggest a real biologic difference in these
diseases or simply highlight methodologic problems in the pooled
analysis. Although the current data suggest that male breast cancer
seems to most closely resemble postmenopausal female breast
cancer, more robust data are needed to confirm this observation.
One of the key requirements for the future management of male
breast cancer is a clear understanding of the molecular pathology
based on robust analysis of large populations.
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The inconsistencies between studies can be illustrated by the
discrepancies between a large American series,46 where hormone re-
ceptor status was similar to that seen in women (81% of tumors
expressed ER, and 74%expressed PgR), and the European Institute of
Oncology (IEO) experience,45 where ER was expressed in 100% of
male breast tumors and PR was expressed in 96%.
The data onHER2 expression inmale breast cancer are similarly
inconsistent. Inone series byBloomet al,50 only one (1.7%)of 58men
with breast cancer had HER2 overexpression by immunohistochem-
istry, and none showed HER2 amplification by fluorescence in situ
hybridization. In the IEO series,45 15% of male breast tumors were
HER2 positive.
Data on other biomarkers of interest are even more sparse and
variable. The current data tend to focus on whether or not a certain
marker is expressed, rather than quantifying the level or degree of
expression. Breast cancers inmen express p53, but results range from
3.7% to20.8%of patientswith positive expression.47,48,51 In one small
study focusingon cytokeratin (CK) expression, 32male breast tumors
were examined for expression of CK5/6, CK14, andCK17 (associated
with basal phenotype) and CK18 and CK19 (associated with luminal
subtype), along with ER and HER2 expression.52 Four tumors dis-
played a basal phenotype pattern of CK expression; the remaining 28
tumors had a luminal-like expression pattern. Interestingly, one tu-
mor example was described in the report in which the basal CKs and
ERwere all highly expressed. CKprofiles suggest that we can differen-
tiate luminal frombasal tumors inmale breast cancer, as is the case for
female breast cancer.
An abstract presented at the 45th AnnualMeeting of the Ameri-
can Society of Clinical Oncology in 2009 by Shak et al53 compared
quantitative gene expressionby sex in tumor specimens submitted for
OncotypeDX(GenomicHealth,RedwoodCity,CA) recurrence score
testing. The analysis included 347 male and 82,434 female tumor
specimens. The distribution of recurrence scores in men and women
was similar; the proportions of tumors with low, intermediate, and
high recurrence scoreswere 53.6%, 35.2%, and11.2%, respectively, in
men and 53.4%, 36.2%, and 10.3%, respectively, in women. Notably,
the level of quantitative ER expression increased with patient age in
women but was essentially stable in men.53 Overall, current data
suggestmore similarities thandissimilarities betweenmale and female
breast cancers; however, additional research on molecular character-
istics of male breast cancer is crucial.
TREATMENT
Themost common surgical procedure formale breast cancer ismod-
ified radical mastectomy. Literature from male breast cancer case
series suggests that modified radical mastectomy is used in approxi-
mately 70%of patients, followedby radicalmastectomy (8% to 30%),
total mastectomy (5% to 14%), and lumpectomy with or without
radiation (1% to13%).54 It is important tonote that in these series, T4
disease represented 20% to 25% of cancers, which likely affected the
choice of surgical procedure. Radical mastectomy was more com-
monly used in older case series, likely reflecting both practice
patterns and later stage at diagnosis of patients in the older series.
Male breast anatomy may also contribute to the increased rate of
radical mastectomy.
Axillary nodal involvement is the strongest predictor of both
local recurrence and metastatic risk and is present in approximately
50% of men with breast cancer.30-32,40,41,55,56 In approximately
40% of patients with nodal involvement, there aremore than three
nodes involved.30,31,40,54 Sentinel lymph node (SLN) sampling has
been examined in numerous small series and seems to be feasible
and accurate.
The predictive value of SLN analysis in male breast cancer was
investigated by the IEO in 32 patients with cN0 disease subjected to
total mastectomy and dissection of the SLN and nonsentinel axillary
lymph nodes.57 The SLN was identified by lymphoscintigraphy with
colloid particles of human serum albumin labeled with technetium-
99m. The SLN was analyzed intraoperatively in frozen sections cut at
50-mintervals. Lymphoscintigraphy successfully identified all of the
SLNs, and the mean number of SLNs was 1.5 (range, one to three
SLNs). In six patients, SLNs (18.75%) were metastatic (four macro-
metastases and twomicrometastases). In four of these six patients, the
SLN was the only lymph node with metastatic deposits, and two
patients had additional positive axillary lymph nodes. The Memorial
Sloan-Kettering Cancer Center recently reviewed their experience
with SLN sampling in male breast cancer.58 Of 78 male patients re-
viewed, SLN sampling was successful in 76 patients, yielding a failure
rate (3%) that was identical to that seen in concurrently evaluated
women with breast cancer. Forty-nine percent of male breast cancer
patients had a positive SLN compared with 31% of women. At a
median follow-up of 28 months, no axillary recurrences were noted.
Similar data have been reported in other, smaller studies, suggesting
that SLN analysis is a reliable tool in male breast cancer patients,
sparing unnecessary axillary lymph node dissection in a significant
fraction (35% in the IEO series) of the patients.
There are few studies describing the use of postmastectomy radi-
ation inmale breast cancer, and all are small retrospective analyses. In
these studies, between 3% and 100% of patients received radiation
therapy, and local recurrence rates ranged from3%to29%.59A recent
review suggested that indications for postmastectomy radiation
Table 1. Comparison of Existing Literature on Receptor Status in Male and Female Breast Cancer
Receptor
Male Breast Cancer Female Breast Cancer
Male-to-Female
Ratio
Mean No. of Male Breast
Cancer Patients on Study
Total No.
of Patients
Receptor-
Positive Patients
Total No.
of Patients
Receptor-
Positive Patients
No. % No. %
ER 1,548 1,269 82 3,755 2,597 69 1.19 34
PgR 1,287 968 75 2,049 1,141 56 1.35 35
HER2 741 250 34 3,755 942 25 1.34 39
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
Korde et al
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should follow recommendations used for treatment of disease in
women, keeping in mind that axillary nodal involvement is a strong
predictor of local recurrence risk.54 In addition, retroareolar location
of tumor andmuscle invasion should be considered as further indica-
tions for locoregional radiation treatment.
Themainstayof systemic therapy forhormone receptor–positive
male breast cancer is hormonal therapy. Tamoxifen is the most
extensively studied. Other hormonal therapies include luteinizing
hormone–releasinghormone (LHRH) agonists, orchidectomy, estro-
gens, andprogestins. Case studies have described the use of aromatase
inhibitors with orwithout concurrent LHRHagonist for treatment of
male breast cancer, but there are no data supporting this approach.
In a recently reported French case series that included 489 men
with breast cancer diagnosed between 1990 and 2005, 72%of patients
received hormonal therapy; themajority of these patients (85%)were
treated with tamoxifen.60 An additional report outlining patterns of
care for male breast cancer in the United States using the SEER data-
base between 2003 and 2004 will be published shortly. In a case series
fromTheUniversity of TexasM.D.AndersonCancerCenter,61which
observed 135 patients for a median follow-up time of 14 years, there
was a clear benefit in terms of both recurrence and overall survival
with hormonal therapy. A majority of patients in this study received
tamoxifen (92%); the remainder received either an LHRH agonist or
megestrol acetate. Other studies have also suggested a benefit for
tamoxifen in the treatment of male breast cancer.32,34,62
Useof adjuvant chemotherapy inmalebreast cancer is associated
with younger age, higher tumor grade, and axillary nodal involve-
ment. In the French series, 6% of patients received chemotherapy
alone, and 28% received the combination of chemotherapy and hor-
monal treatment.60 Of patients receiving chemotherapy, 73% were
treated with an anthracycline-based regimen. In the M.D. Anderson
CancerCenter report,61 25%ofpatients receivedchemotherapyalone,
and 37% of patients received chemotherapy and hormonal therapy.
Theuse of chemotherapywas associatedwith anonsignificantly lower
risk of death (hazard ratio 0.78). A second study looking at 20-year
survival after chemotherapy with cyclophosphamide, fluorouracil,
andmethotrexate inmalebreast cancer suggestedabenefit forpatients
with lymph node involvement.63 Because chemotherapy benefits in
general aremore apparent in endocrine-nonresponsive breast cancer,
in high-risk groups, and in younger patients, it is likely more difficult
to detect a chemotherapy benefit in male breast cancer, where the
majority of tumors are ER positive and where patients are older and
have multiple comorbidities.
One study has examined the effect of sociodemographic and
treatment factors on outcomes in male breast cancer.41 This study
included510menwithbreast cancer (456white and34blackpatients)
fromtheSEERregistry (1992 to2002)whowereover the ageof 65 and
covered byMedicare Parts A andB. Two thirds of themenwith breast
cancer were referred to a medical oncologist, and approximately a
quarter of these patients received adjuvant chemotherapy. The stron-
gest predictors of who would receive chemotherapy included age
(youngermenweremore likely to receive chemotherapy) and stage of
disease. Hormone receptor positivity and comorbidities were in-
versely related to chemotherapyuse.Ofnote, althoughnot statistically
significant, black men were approximately 50% less likely to be re-
ferred to amedical oncologist and to receive chemotherapy. Approx-
imately 50% of the sample population had died after a median
follow-up time of 5 years; a slightly higher proportion of blacks
died in the follow-up period. Among whites, only approximately
25% of the deaths were reported to be breast cancer related, whereas
approximately 60%of the deaths among blackswere defined as breast
cancer–related deaths. In amultivariate analysis adjusted for sociode-
mographics, known prognostic factors, and treatment received, there
was approximately a three-fold increased riskofbreast cancer–specific
mortality for black men compared with their white counterparts.
However, becauseonly 34blackmenwithbreast cancerwere included
in this series, these data should be interpreted with caution.
Todate, in theUnited States, there has only beenoneprospective
clinical trial inmale breast cancer, fielded by the Southwest Oncology
Group. The hypothesiswas that the efficacy of aromatase inhibitors as
single-agent therapy formalebreast cancer shouldnotbe extrapolated
from the data on their use in women. The study was a single-arm,
phase II trial with a goal of 56 patients with static or recurring disease
who were ER positive. Patients were to receive the combination of
anastrozole (daily) and goserelin acetate (monthly injections). The
primaryendpointwasprogression-free survival.Thestudyplannedto
examine serial serumendocrine levels and to examine the genomics of
drugmetabolism with anastrozole in men. The study closed after less
than 2 years with no patients accrued. The challenges faced were
mainly logistic; sites were reluctant to activate a study (only 26 South-
west Oncology Group sites activated the study) and undergo the
administrative costs for such a rare disease.
DISCUSSION AND PANEL RECOMMENDATIONS
Panel members agreed that based on current epidemiologic and his-
topathologic data, male breast cancer seems to resemble postmeno-
pausal hormone receptor–positive disease in women. However, in
view of the paucity of data, the rarity of the disease, and different
hormonal milieu, male breast cancer should be considered andman-
aged as a distinct entity. Although there seem to be racial and ethnic
differences in both incidence and survival ofmale breast cancer, addi-
tional data are needed to confirm these observations. Discussants
agreed that given the rarity of male breast cancer, large collaborative
efforts are crucial to moving research forward. Two major consortial
efforts were discussed, one led from the United States and one from
the BIG and the European Organisation for Research and Treatment
of Cancer. The National Cancer Institute and NIH Office of Rare
Diseases areplanninganepidemiologically focusedmalebreast cancer
meeting. It will bring together investigators from large cohort studies
with bankedblood andbiomarker data to further examine risk factors
for male breast cancer and to look at specific associations between
biomarkers such as endogenoushormone levels andbreast cancer risk
in men.
The second planned research collaboration is an International
Male Breast Cancer Program, coordinated by the European Organi-
sation for Research and Treatment of Cancer under the BIG and
NABCG networks. This program has three planned parts. The main
objective of part 1, or the retrospective part, is to perform a meta-
analysis of clinical data and a central pathology review of tumor
specimens from patients withmale breast cancer diagnosed at partic-
ipating institutions over the last 20 years. This effort has the poten-
tial to overcome many of the difficulties seen in individual studies
where biomarker data suffered from lack of harmonization in both
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definitions and techniques used. Proposed analyses using paraffin-
embedded tumor material include quantitative ER and PgR protein
levels, HER2 status, Ki67, androgen receptors, cyclin D1, p21, p27,
intertumoral aromatase, andsurvivin.Geneexpressionprofiling stud-
ies using frozen tumor material are planned to evaluate the presence
and relative incidence of the breast cancer biologic subtypes (basal,
luminal, and HER2), the prognostic value of the 70-gene profile, the
wound signature, and the stromal signature, among others.
Part 2, or the prospective part, of the program consists of a
prospective international registry of all patients withmale breast can-
cer diagnosed at participating institutions for a period of 2 years. The
registry would initially use a virtual tumor bank until funding is
secured for central analysis of thebiologicmaterial collected (paraffin-
embedded and frozen tumor samples and blood/serum). Addition-
ally, data on demographics, risk factors, treatment, and outcome will
be collected through a remote data capture system.
Data collected from the first two parts of the International Male
Breast Cancer Programwill enable us to determine the feasibility of a
randomized clinical trial that could be launched as part 3 of the
program. In view of the failure of previous attempted male breast
cancer clinical trials to accrue patients, it is crucial to establish a fully
committed global effort to successfully run such a trial.
Todate, farmore than19 researchgroupshave expressed interest
in participating in the retrospective component of this effort, which
would provide approximately 1,700 patients. It is estimated that par-
affin blocks can be obtained in 75% to 80% of patients, with frozen
material available for25%to30%.For theprospectivepart,more than
16 researchgroupshave confirmed their interest,which should lead to
accrual of approximately 100 patients per year.
Funding for such a non–drug-related, purely academic effort is
an important hurdle. Thus far, grants have been obtained from the
Breast Cancer Research Foundation for the retrospective part and
from the European Breast Cancer Conference for the prospective
registry. Efforts continue to be made to find the remaining funds
needed for this major cooperative academic endeavor for male breast
cancer research.
Panel members noted that efforts to understand the biology of
male breast cancer, such as those described earlier, are essential to
guiding therapy.Most data regarding treatment ofmale breast cancer
is retrospective in nature and comes from small single-institution
series; thus, the choice of treatment modalities is generally guided by
extrapolation of data from female breast cancer. The established stan-
dard of care for male breast cancer is modified radical mastectomy
followed by tamoxifen for endocrine-responsive positive disease, al-
though other options are being explored. SLN biopsy seems to be
feasible and accurate inmenwith small tumors and clinically negative
axillae. Chemotherapy seems to benefit patients with endocrine-
nonresponsive disease, large tumors, and/or node-positive disease.
Patterns of care studies suggest that aromatase inhibitors are
being used in the community for treatment of hormone receptor–
positive disease despite a lack of solid data supporting their use. In-
deed, this is in contradiction to biologic hypotheses that aromatase
inhibitors might increase circulating testosterone in men, leading to
an increase in androgen available for conversion to estrogen.64 Aside
from case reports, there are no clinical studies addressing the
efficacy of aromatase inhibitors for male breast cancer. Biologic
data suggest that if used in men, aromatase inhibitors should be
combinedwith surgical ormedical orchidectomy.64,65 The consen-
sus among panel members was that although it would be reason-
able to study aromatase inhibitors in male breast cancer, tamoxifen
should remain the standard of care for adjuvant treatment of
endocrine-responsive male breast cancer and that use of aromatase
inhibitors for male breast cancer should be limited to the clinical trial
setting until additional data on aromatase inhibitors in male breast
cancer are available. To this end, a small study analyzing the phar-
macokinetics and pharmacodynamics of aromatase inhibitors in
men is being run as a joint effort between some members of the
panel. For the treatment of metastatic tamoxifen-resistant male
breast cancer, aromatase inhibitors may be considered but should
only be administered in combination with surgical or medical
orchidectomy (LHRH agonist).
Members felt that the development of treatment guidelines for
male breast cancer would be beneficial. To our knowledge, the Arbe-
itsgemeinschaftGyna¨kologischeOnkologie is currently the only orga-
nization with published guidelines for male breast cancer, and the
majority of data used to form these recommendations come from
small case series and expert opinion. The panel stressed that male
breast cancer should be considered a rare and unique disease, rather
than being considered as analogous to postmenopausal female breast
cancer. Treatment of male breast cancer should be driven by data
collected from studies that includemale participants. Furthermore, it
was felt that an educational session at one of the large breast cancer
meetingswouldbehelpful in educatingphysicians on the current data
regarding treatment options for male breast cancer.
Several discussion points regarding the prospect of clinical
trials in male breast cancer were raised. First, it was felt that more
etiologic data are necessary before embarking on clinical trials.
Second, given the past experience with poor accrual, a large-scale
international effort with a pre-existing infrastructure is strongly
advised if a trial of this nature is to succeed; to this end, the
International Male Breast Cancer Program is being developed
through the BIG and NABCG networks. In addition, awareness at
the community oncology level of such an effort is crucial. This
could be facilitated through educational sessions at national meet-
ings and potentially through raising awareness of clinical trial
availability at the advocacy level.
Several trial design issueswere also discussed. Because themajor-
ity of male breast tumors are endocrine responsive, the most logical
first step would be to develop a trial on endocrine therapy options for
these patients. One possibility would be to create a trial looking at
tamoxifen versus an aromatase inhibitor with a safety, rather than an
efficacy, end point. This would facilitate performing a smaller study
and would provide important toxicity data on tamoxifen inmen (for
which there is scant informationcurrently), aswell aspreliminarydata
on aromatase inhibitors. A second suggestion was the creation of a
blanket orphan disease protocol that could be opened at multiple
institutions and could facilitate gathering information on many of
the rarer subsets of patients with breast cancer, including male
breast cancer, inflammatory breast cancer, breast cancer in pregnant
women, and breast cancer after treatment for Hodgkin’s lymphoma.
A third option would be to have a separate stratum for male breast
cancer in large clinical trials in female breast cancer; this would allow
for the collection of data on male breast cancer across studies that
could be looked at in meta-analyses.
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CONCLUSION
The panel concluded that much still needs to be learned about male
breast cancer. It is clear that for this disease, and indeed formany rare
diseases, the key to understanding is the pooling of data from a wide
range of sources. International consortia are essential for moving
forward inourunderstandingofmale breast cancer.Current efforts at
pooling epidemiologic data, clinical information, and tumor speci-
menswill lead toagreaterunderstandingof theetiologyof thisdisease.
Current international collaborations will also facilitate the future
planning of successful clinical trials that can address essential ques-
tions in the treatment of male breast cancer. Education of both pa-
tients and providers is needed to increase awareness of male breast
cancer, to guide evidence-based treatment, and to encourage enroll-
ment onto future clinical and biologic studies aimed at optimizing
treatment for this rare disease.
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